ID

31770

Description

Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ); ODM derived from: https://clinicaltrials.gov/show/NCT00773838

Link

https://clinicaltrials.gov/show/NCT00773838

Keywords

Versions (1)
  1. 9/27/18 9/27/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 27, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

English

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient is 18 years of age or older
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patient has an established diagnosis of multiple myeloma based on myeloma diagnostic criteria
Description

Multiple Myeloma

Data type

boolean

Alias
UMLS CUI [1]
C0026764
patient must have adequate organ function
Description

Organ function

Data type

boolean

Alias
UMLS CUI [1]
C0678852
patient is refractory to prior bortezomib regimen and have also been exposed to prior imid (thalidimide or lenalidmide)
Description

Bortezomib refractory | Exposure to Imide | Exposure to Thalidomide | Exposure to Lenalidomide

Data type

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0020926
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C0039736
UMLS CUI [4,1]
C0332157
UMLS CUI [4,2]
C1144149
patient has relapsed and refractory multiple myeloma after at lest 2 prior treatment regimens
Description

Relapse multiple myeloma | Refractory multiple myeloma | Status post Therapeutic procedure Quantity

Data type

boolean

Alias
UMLS CUI [1]
C2349261
UMLS CUI [2]
C0278620
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C1265611
patient is relapsed, refractory, intolerant, and/or ineligible (in the opinion of the investigator) to other therapies including an imid (thalidomide or lenalidomide)
Description

Other Therapy Relapse | Other Therapy refractory | Intolerant Other Therapy | Ineligibility Other Therapy | Imide | Thalidomide | lenalidomide

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0277556
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0205394
UMLS CUI [2,3]
C0205269
UMLS CUI [3,1]
C0231200
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C0205394
UMLS CUI [4,1]
C1512714
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C0205394
UMLS CUI [5]
C0020926
UMLS CUI [6]
C0039736
UMLS CUI [7]
C1144149
patient is refractory to bortezomib (no response on prior bortezomib containing regimen or progression on or within 60 days of bortezomib containing regimen
Description

Bortezomib refractory | Therapeutic procedure Containing Bortezomib | Disease Progression

Data type

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0332256
UMLS CUI [2,3]
C1176309
UMLS CUI [3]
C0242656
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient has known hypersensitivity to any components of bortezomib or vorinostat
Description

Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0672708
UMLS CUI [2,3]
C1705248
patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
Description

Allogeneic bone marrow transplantation | Bone Marrow Transplantation Planned

Data type

boolean

Alias
UMLS CUI [1]
C0149615
UMLS CUI [2,1]
C0005961
UMLS CUI [2,2]
C1301732
patient has known hypersensitivity to any components of bortezomib or vorinostat
Description

Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0672708
UMLS CUI [2,3]
C1705248
patient has active hepatitis b or c, plasma cell leukemia, or is hiv positive
Description

Hepatitis B | Hepatitis C | Leukemia, Plasma Cell | HIV Seropositivity

Data type

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0023484
UMLS CUI [4]
C0019699
Back to the top of the page

Similar models

Eligibility Relapsed or Refractory Multiple Myeloma NCT00773838

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patient is 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Multiple Myeloma
Item
patient has an established diagnosis of multiple myeloma based on myeloma diagnostic criteria
boolean
C0026764 (UMLS CUI [1])
Organ function
Item
patient must have adequate organ function
boolean
C0678852 (UMLS CUI [1])
Bortezomib refractory | Exposure to Imide | Exposure to Thalidomide | Exposure to Lenalidomide
Item
patient is refractory to prior bortezomib regimen and have also been exposed to prior imid (thalidimide or lenalidmide)
boolean
C1176309 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0020926 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C0039736 (UMLS CUI [3,2])
C0332157 (UMLS CUI [4,1])
C1144149 (UMLS CUI [4,2])
Relapse multiple myeloma | Refractory multiple myeloma | Status post Therapeutic procedure Quantity
Item
patient has relapsed and refractory multiple myeloma after at lest 2 prior treatment regimens
boolean
C2349261 (UMLS CUI [1])
C0278620 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
Other Therapy Relapse | Other Therapy refractory | Intolerant Other Therapy | Ineligibility Other Therapy | Imide | Thalidomide | lenalidomide
Item
patient is relapsed, refractory, intolerant, and/or ineligible (in the opinion of the investigator) to other therapies including an imid (thalidomide or lenalidomide)
boolean
C0087111 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0231200 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0205394 (UMLS CUI [3,3])
C1512714 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0205394 (UMLS CUI [4,3])
C0020926 (UMLS CUI [5])
C0039736 (UMLS CUI [6])
C1144149 (UMLS CUI [7])
Bortezomib refractory | Therapeutic procedure Containing Bortezomib | Disease Progression
Item
patient is refractory to bortezomib (no response on prior bortezomib containing regimen or progression on or within 60 days of bortezomib containing regimen
boolean
C1176309 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0332256 (UMLS CUI [2,2])
C1176309 (UMLS CUI [2,3])
C0242656 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component
Item
patient has known hypersensitivity to any components of bortezomib or vorinostat
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0672708 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Allogeneic bone marrow transplantation | Bone Marrow Transplantation Planned
Item
patient has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy
boolean
C0149615 (UMLS CUI [1])
C0005961 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
Hypersensitivity Bortezomib Component | Hypersensitivity Vorinostat Component
Item
patient has known hypersensitivity to any components of bortezomib or vorinostat
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0672708 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
Hepatitis B | Hepatitis C | Leukemia, Plasma Cell | HIV Seropositivity
Item
patient has active hepatitis b or c, plasma cell leukemia, or is hiv positive
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
C0023484 (UMLS CUI [3])
C0019699 (UMLS CUI [4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial